The effects AZD8529 on ketamine-induced impairment of working memory in healthy volunteers
Study identifier:D2285M00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Single Center, Double-Blind, Randomized, Double Dummy, Placebo-Controlled, Three-Period Crossover Study to Assess the Effects of a mGluR2/3 Positive Allosteric Modulator [AZD8529] Upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex
Medical condition
Healthy, Memory impairment
Phase
N/A
Healthy volunteers
Yes
Study drug
AZD8529, Placebo to match AZD8529
Sex
All
Actual Enrollment
20
Study type
Interventional
Age
21 Years - 45 Years
Date
Study Start Date: 01 Feb 2010
Primary Completion Date: 01 Apr 2011
Study Completion Date: 01 Apr 2011
Study design
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 May 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 180 mg of AZD8529 | Drug: AZD8529 6 capsules by mouth 1 time 12 to 24 prior to assessments Drug: Placebo to match AZD8529 6 capsules by mouth 1 time 12 to 24 hours prior to assessments |
| Experimental: 2 50 mg AD8529 | Drug: AZD8529 6 capsules by mouth 1 time 12 to 24 prior to assessments Drug: Placebo to match AZD8529 6 capsules by mouth 1 time 12 to 24 hours prior to assessments |
| Placebo Comparator: 3 Placebo | Drug: AZD8529 6 capsules by mouth 1 time 12 to 24 prior to assessments Drug: Placebo to match AZD8529 6 capsules by mouth 1 time 12 to 24 hours prior to assessments |
Contacts
Investigators
Principal Investigator
John Krystal
Chair, Department of PsychiatryYale University School of MedicineChief of Psychiatry, Yale-New Haven Hospital
